<DOC>
	<DOCNO>NCT02454712</DOCNO>
	<brief_summary>PF614 oxycodone prodrug design extended-release oxycodone comparable OxyContin . This Single Ascending Dose ( SAD ) study design ass safety pharmacokinetics ( PK ) PF614 comparison standard dose OxyContin .</brief_summary>
	<brief_title>Study PF614 Compared OxyContin® Healthy Volunteers</brief_title>
	<detailed_description>This Phase 1 randomize , single-center , SAD study 6 cohort 8 healthy male and/or female subject . The study evaluate safety PK PF614 PK oxycodone dose sufficient characterize extent plasma oxycodone produce maintain follow oral ingestion PF614 . The PK prodrug fragment also evaluate . There parallel study arm cohort dose use oral OxyContin® active comparator . Subjects receive PF614 ( n=6 ) OxyContin comparator ( n=2 ) orally fast state . In addition , subject start Cohort 1C receive naltrexone 14 hour pre-dose , 2 hour pre-dose 10 hour post dose block effect oxycodone . The start dose administration PF614 15 mg . The low available dose OxyContin , 10 mg , use comparator first cohort . PK assessment conduct cohort compare oxycodone area curve ( AUC ) PF614 OxyContin determine appropriate dose subsequent cohort . In Cohort 6 ( fed subject ) , subject ( n=8 ) receive PF614 naltrexone dos administer Cohort 5 evaluate PK safety PF614 feed vs. fast state . Subjects Cohort 6 receive Food Drug Administration-defined high-fat , high-calorie breakfast 30 minute prior study drug administration .</detailed_description>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>1 . Males female , age 1850 year ( inclusive ) good general health ; 2 . Body mass index ( BMI ) 18.0 32.0 kg/m2 ( inclusive ) ; 3 . Minimum weight 50.0 kg , inclusive ; 4 . Subjects must negative screen drug abuse , cotinine , alcohol , hepatitis Bsurface antigen , hepatitis C antibody antibody HIV 1 2 ; 5 . Female subject must negative serum pregnancy test screen negative pregnancy test Day 1 ; 6 . Females childbearing potential male female partner ( ) childbearing potential must agree use 2 form contraception , 1 must barrier method , study 90 day last drug administration . Acceptable barrier form contraception condom diaphragm . Acceptable nonbarrier form contraception study nonhormonal intrauterine device ( IUD ) , oral contraceptive and/or spermicide ; 7 . Male subject must agree donate sperm throughout study 90 day last study drug administration ; 8 . Subjects must normal evidence clinically significant finding physical examination 12lead electrocardiogram ( ECG ) accord Investigator , normal vital sign ( respiratory rate 10 18 breath per minute , blood pressure 100139/5089 mmHg , heart rate 40100 beat per minute , temperature 96.44°F 100.04°F ( 35.8°C 37.8°C ) , oxygen saturation ( SpO2 ) &gt; 97 % absence supplemental oxygen ; 9 . Clinical laboratory value must within normal limit define clinical laboratory , unless Investigator decide outofrange value clinically significant ; 10 . Subjects must able provide meaningful write informed consent ; 11 . Subjects must willing able follow study instruction likely complete study requirement . 1 . History allergy sensitivity oxycodone , OxyContin , opiate , naltrexone , naloxone ; 2 . History loud snore sleep apnea ; 3 . History medical problem encounter opioid therapy ; 4 . Urinary cotinine level indicative smoke history regular use tobaccocontaining nicotinecontaining product within 2 month prior screen ; 5 . History alcoholism drug abuse ( prescription illicit drug ) accord Diagnostic Statistical Manual IVText Revision ( DSM IVTR ) criteria ; 6 . Use prescription medication within 14 day study drug administration , except contraceptive medication use female subject ; use overthecounter ( OTC ) medication within 7 day prior study drug administration ; 7 . Use opioid within 30 day prior screen ; 8 . Donation blood within 60 day prior screen ; 9 . Donation plasma , platelet , white blood cell within 7 day prior dose ; 10 . Acute illness ( eg , gastrointestinal illness , infection influenza , upper respiratory tract infection , know inflammatory process ) within 7 day dose 11 . History gastrointestinal disturbance require frequent use antacid ; 12 . History clinically significant gastrointestinal disease and/or surgery would result subject 's inability absorb metabolize study drug ( eg , gastrectomy , gastric bypass , cholecystectomy ) ; 13 . Anticipated need surgery hospitalization study followup period ; 14 . Dosing investigational drug participation investigation device study within 30 day 5 halflives first dose study drug ; 15 . Women lactate ; 16 . Any condition , , Investigator 's opinion , ( ) put subject increase risk , ( ii ) could confound study result ( iii ) may interfere significantly subject 's participation study ( IV ) potential limit subject 's ability complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prodrug</keyword>
	<keyword>PF614</keyword>
	<keyword>oxycodone extended-release</keyword>
	<keyword>oral</keyword>
</DOC>